Key facts
- This page summarizes Bruce Keyt's Form 4 filing for IGM Biosciences, Inc. (IGMS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Mar 2024, 19:22.
Bruce Keyt - 26 Mar 2024 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- IGMS
- Reported as of
- 26 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Mar 2024, 19:22:28 UTC
- Prior SEC filing
- 15 Mar 2024
- Next SEC filing
- 18 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Misbah Tahir, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bruce Keyt filed Form 4 for IGM Biosciences, Inc. (IGMS) on 28 Mar 2024.
Change
- Previous filing in this sequence was filed on 15 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IGMS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +24,019
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 195,875
- Date
- 26 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
IGMS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,039
- Date
- 26 Mar 2024
- Ownership
- See footnote
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These securities are restricted stock units (RSUs), granted pursuant to the election by the Reporting Person to receive RSUs in lieu of an earned cash bonus for performance in fiscal year 2023. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs shall vest in December 2024, provided that the Reporting Person remains a service provider through the vesting date.
Footnote F2
The securities are held directly by the reporting person's spouse.